SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 5.5 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS

被引：0
|
作者：
Genovese, M. C. [1 ]
Smolen, J. S. [2 ]
Takeuchi, T. [3 ]
Hyslop, D. [4 ]
Macias, W. L. [4 ]
Rooney, T. P. [4 ]
Chen, L. [4 ]
Dickson, C. L. [4 ]
Camp, J. R. [4 ]
Cardillo, T. E. [4 ]
Ishii, T. [5 ]
Winthrop, K. L. [6 ]
Garcia, E. G. [4 ]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Med Univ Vienna, Vienna, Austria
[3] Keio Univ, Tokyo, Japan
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Kobe, Hyogo, Japan
[6] Oregon Hlth & Sci Univ, Portland, OR USA
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
375
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [21] SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS
    Genovese, M.
    Smolen, J.
    Takeuchi, T.
    Hyslop, D.
    MacIas, W.
    Rooney, T.
    Chen, L.
    Dickson, C.
    Riddle, J.
    Cardillo, T.
    Winthrop, K.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 31 - 31
  • [22] SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS
    Genovese, M.
    Smolen, J.
    Takeuchi, T.
    Hyslop, D.
    MacIas, W.
    Rooney, T.
    Chen, L.
    Dickson, C.
    Riddle, J.
    Cardillo, T.
    Winthrop, K.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 28 - 28
  • [23] Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis Up to 3 Years: an Updated Integrated Safety Analysis
    Schwartzman, Sergio
    Deodhar, Atul
    Combe, Bernard
    Accioly, Ana
    Kronbergs, Andris
    Janos, Boris
    Zhu, Danting
    Sandoval, David
    Rahman, Proton
    Poddubnyy, Denis
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 828 - 828
  • [24] SAFETY PROFILE OF IXEKIZUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS UP TO 3 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS
    Tay, Tien
    Schwartzman, Sergio
    Deodhar, Atul
    Combe, Bernard
    Accioly, Ana
    Kronbergs, Andris
    Janos, Boris
    Zhu, Danting
    Sandoval, David
    Rahman, Proton
    Poddubnyy, Denis
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 42 - 42
  • [25] Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
    Schwartzman, Sergio
    Deodhar, Atul
    Combe, Bernard
    Accioly, Ana
    Kronbergs, Andris
    Janos, Boris
    Zhu, Danting
    Calderon, David Sandoval
    Rahman, Proton
    Poddubnyy, Denis
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3820 - 3823
  • [26] Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years
    Winthrop, Kevin
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Kivitz, Alan
    Matzkies, Franziska
    Genovese, Mark
    Jiang, Deyuan
    Chen, Kun
    Bartok, Beatrix
    Jahreis, Angelika
    Besuyen, Robin
    Burmester, Gerd
    Gottenberg, Jacques-Eric
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [27] Safety of baricitinib: update from up to 6 years of treatment in rheumatoid arthritis clinical trials
    Hall, S.
    Genovese, M.
    Smolen, J.
    Weinblatt, M.
    Winthrop, K.
    Taylor, P.
    Burmester, G.
    Van Den Bosch, F.
    Dudler , J.
    Rooney, T.
    Dickson, C.
    Issa, M.
    Ishii, T.
    Saifan, C.
    Adhami, P.
    Takeuchi, T.
    SWISS MEDICAL WEEKLY, 2019, : 9S - 9S
  • [28] INTEGRATED SAFETY PROFILE OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Cohen, Stanley B.
    van Vollenhoven, Ronald
    Curtis, Jeffrey R.
    Calabrese, Leonard
    Zerbini, Cristiano A. F.
    Tanaka, Yoshiya
    Bessette, Louis
    Richez, Christophe
    Lagunes-Galindo, Ivan
    Liu, Jianzhong
    Camp, Heidi S.
    Song, Yanna
    Anyanwu, Samuel I.
    Burmester, Gerd R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S105 - S105
  • [29] INTEGRATED SAFETY PROFILE OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Cohen, S. B.
    Van Vollenhoven, R.
    Curtis, J. R.
    Calabrese, L.
    Zerbini, C.
    Tanaka, Y.
    Bessette, L.
    Richez, C.
    Lagunes-Galindo, I.
    Liu, J.
    Camp, H.
    Song, Y.
    Anyanwu, S.
    Burmester, G. R.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 328 - 329
  • [30] Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
    Smolen, Josef S.
    Genovese, Mark C.
    Takeuchi, Tsutomu
    Hyslop, David L.
    Macias, William L.
    Rooney, Terence
    Chen, Lei
    Dickson, Christina L.
    Camp, Jennifer Riddle
    Cardillo, Tracy E.
    Ishii, Taeko
    Winthrop, Kevin L.
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (01) : 7 - 18
12345